Entheon Biomedical

Entheon Biomedical is a Vancouver-based neurotechnology company focused on developing DMT-assisted therapies for the treatment of addiction and substance use disorders. The company's clinical programs center on the therapeutic use of N,N-Dimethyltryptamine, a rapidly acting psychedelic compound, combined with structured psychological support to address conditions including alcohol dependence and nicotine addiction. Entheon's approach integrates pharmacological intervention with evidence-based psychotherapeutic frameworks, reflecting a growing body of research suggesting that psychedelic compounds can facilitate meaningful behavioral change in treatment-resistant populations. The company operates at the intersection of psychiatry, neuroscience, and drug development, positioning psychedelic medicine as a viable clinical pathway rather than an alternative treatment.

Entheon Biomedical is publicly traded on the Canadian Securities Exchange under the ticker ENBI, providing transparency and access to capital as it advances its clinical pipeline. The company has worked to establish proprietary protocols for DMT administration, focusing on dosing parameters, session structure, and patient safety frameworks that could support regulatory submissions. As the psychedelic therapeutics sector moves increasingly toward formal clinical trials and regulatory engagement, Entheon's programs are designed to meet the evidentiary standards required by health authorities. Their progress reflects a broader industry shift in which psychedelic-assisted therapies are transitioning from research curiosity to structured pharmaceutical development.

Entheon Biomedical represents a meaningful contributor to the emerging wave of companies challenging conventional approaches to addiction treatment, a space where therapeutic innovation has historically lagged behind need. Addiction and substance use disorders impose substantial economic and social costs globally, and existing pharmacological and behavioral interventions show significant limitations in long-term efficacy. By advancing DMT as a potential therapeutic agent, Entheon contributes to the scientific and commercial infrastructure being built around psychedelic medicine, helping to normalize its role within mainstream neurotechnology. Their work underscores how the neurotech industry is expanding beyond devices and diagnostics to include neurochemical interventions that target the biological and psychological roots of mental health conditions.